Intra-Cellular Therapies (NASDAQ:ITCI) Earns Buy Rating from Needham & Company LLC
MarketBeatNeedham & Company LLC restated a “buy” rating and issued a $100.00 price target on shares of Intra-Cellular Therapies in a research note on Wednesday.
Needham & Company LLC restated a “buy” rating and issued a $100.00 price target on shares of Intra-Cellular Therapies in a research note on Wednesday.